Gapping down
In reaction to earnings/guidance:
- FAST -3.2%
Other news:
- GOSS -28.3% (announced topline results from its Phase 2b LEDA trial in patients with moderate-to-severe eosinophilic asthma and its Phase 2 TITAN trial in patients with chronic rhinosinusitis)
- VYGR -11.8% (notified by FDA of clinical hold for IND submission for VY-HTT01)
- RCL -5.7% (announces proposed offering of common stock; commences $500 mln a private offering of senior convertible notes to be issued by the Company due 2023)
- AMC -3.4% (provided operations update; continues to explore potential sources of additional liquidity)
- JNJ -1.4% (temporarily pauses all dosing in its Janssen COVID-19 vaccine candidate clinical trials due to an unexplained illness in a study participant; also reported earnings)
- V -1% (attributed to block trade pricing)
Analyst comments:
- BYND -3.6% (downgraded to Underperform from Mkt Perform at Bernstein)
- ILMN -2.1% (downgraded to Neutral from Buy at Guggenheim)
- AAL -1.9% (downgraded to Negative from Neutral at Susquehanna)
- VMC -1.4% (downgraded to Neutral from Buy at BofA Securities)